These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25608124)

  • 41. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration.
    Quadri R; Comino I; Scarzella L; Cacioli P; Zanone MM; Pipieri A; Bergamasco B; Chiandussi L
    Funct Neurol; 2000; 15(2):81-6. PubMed ID: 10916719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches.
    Dashtipour K; Tafreshi A; Lee J; Crawley B
    Neurodegener Dis Manag; 2018 Oct; 8(5):337-348. PubMed ID: 30223711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fundamental frequency change during offset and onset of voicing in individuals with Parkinson disease.
    Goberman AM; Blomgren M
    J Voice; 2008 Mar; 22(2):178-91. PubMed ID: 16950600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alpha-dihydroergocryptine in the long-term therapy of Parkinson's disease.
    Mailland E; Magnani P; Ottillinger B
    Arzneimittelforschung; 2004; 54(10):647-54. PubMed ID: 15553103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA; Gilhus NE
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stimulation of the pedunculopontine nucleus area in Parkinson's disease: effects on speech and intelligibility.
    Pinto S; Ferraye M; Espesser R; Fraix V; Maillet A; Guirchoum J; Layani-Zemour D; Ghio A; Chabardès S; Pollak P; Debû B
    Brain; 2014 Oct; 137(Pt 10):2759-72. PubMed ID: 25080284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.
    Krack P; Batir A; Van Blercom N; Chabardes S; Fraix V; Ardouin C; Koudsie A; Limousin PD; Benazzouz A; LeBas JF; Benabid AL; Pollak P
    N Engl J Med; 2003 Nov; 349(20):1925-34. PubMed ID: 14614167
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy.
    Bhidayasiri R; Jitkritsadakul O; Boonrod N; Rerknimitr R
    Clin Neurol Neurosurg; 2014 Jan; 116():1-3. PubMed ID: 24388506
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Advanced Parkinson's disease].
    Ziégler M
    Psychol Neuropsychiatr Vieil; 2006 Dec; 4 Spec No 1():S5-10. PubMed ID: 23631042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states.
    Goberman A; Coelho C; Robb M
    J Commun Disord; 2002; 35(3):217-39. PubMed ID: 12064785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The response of the apparent receptive speech disorder of Parkinson's disease to speech therapy.
    Scott S; Caird FI
    J Neurol Neurosurg Psychiatry; 1984 Mar; 47(3):302-4. PubMed ID: 6707678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Voice Quality and Orofacial Strength as Outcome of Levodopa Effectiveness in Patients with Early Idiopathic Parkinson Disease: A Preliminary Report.
    Lechien JR; Blecic S; Ghosez Y; Huet K; Harmegnies B; Saussez S
    J Voice; 2019 Sep; 33(5):716-720. PubMed ID: 29724466
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of oral levodopa treatment on articulatory function in Parkinson's disease: preliminary results.
    Cahill LM; Murdoch BE; Theodoros DG; Triggs EJ; Charles BG; Yao AA
    Motor Control; 1998 Apr; 2(2):161-72. PubMed ID: 9644287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved Estimation of Parkinsonian Vowel Quality through Acoustic Feature Assimilation.
    Gaballah A; Parsa V; Cushnie-Sparrow D; Adams S
    ScientificWorldJournal; 2021; 2021():6076828. PubMed ID: 34335114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy.
    Rusz J; Tykalova T; Novotny M; Zogala D; Sonka K; Ruzicka E; Dusek P
    Neurology; 2021 Nov; 97(21):e2124-e2135. PubMed ID: 34607922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Color vision impairment in Parkinson's disease.
    Piro A; Tagarelli A; Nicoletti G; Fletcher R; Quattrone A
    J Parkinsons Dis; 2014; 4(3):317-9. PubMed ID: 24796233
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.